Received Oct 7, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| COVID19 | COVID19 (COVID19 (MODERNA)) | MODERNA | UNK | — | IM |
diabetes; COPD; This spontaneous case was reported by a consumer and describes the occurrence of DIABETES MELLITUS (diabetes) in a female patient of an unknown age who received SPIKEVAX NOS (SPIKEVAX NOS) for COVID-19 prophylaxis. The occurrence of additional non-serious events is detailed below. No Medical History information was reported. On an unknown date, the patient received dose of SPIKEVAX NOS (SPIKEVAX NOS) (Intramuscular use) 1 dosage form. On an unknown date, the patient experienced DIABETES MELLITUS (diabetes) (seriousness criterion medically significant) and CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD). At the time of the report, DIABETES MELLITUS (diabetes) and CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) outcome was unknown. The action taken with SPIKEVAX NOS (SPIKEVAX NOS) (Intramuscular use) was unknown. No concomitant medication was reported. The reporter was inquiring about the lower dose of Moderna's COVID-19 vaccine for seniors, questioning its efficacy compared to the standard dose and whether it's suitable for patients with existing health conditions, such as COPD and diabetes. It was reported that the, the patient was interested in taking Moderna Vaccine only as she took all her pervious COVID Vaccines from Moderna. It was unknown if the patient experienced any additional symptoms or events. No treatment information was provided.; Reporter's Comments: Given the chronic nature and pathophysiology of Chronic Obstructive Pulmonary Disease (COPD), a causal relationship with vaccination is considered unlikely. The benefit-risk relationship of product is not affected by this report.